Abstract 4378: BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Carlos Ernesto Stahlhut Espinosa, Kanchan Singh, Zuhui Zhang, Kyle Sullivan, Nadege Gitego, Megan Rigby, Roger Ma, Patrick Alexander, Saman Setoodeh, Jin Shu, Ken Lin, Dana Rabara, Erik Larsen, Alok Sharma, Albert Chan, Brian P. Smith, Andrew Stephen, Yue Yang, Jun Pei, Felice C. Lightstone, Dhirendra Simanshu, Rui Xu, Chunmei Ji, Keshi Wang, Bin Wang, Kerstin Sinkevicius, Dwight V. Nissley, Eli Wallace, Frank McCormick, Anna E. Maciag, Pedro J. Beltran
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4409633147